NEW YORK (GenomeWeb) – Applied BioCode today said it has expanded an existing licensing and supply agreement with PerkinElmer for the use of Applied BioCode's Barcoded Magnetic Bead technology.
The amended non-exclusive deal provides PerkinElmer access to Applied BioCode's 4,096-plex BMB patents, as well as the BioCode MDx 3000 high-throughput system for the Asian markets. PerkinElmer will develop market-specific multiplexed molecular diagnostics for infectious diseases for the BioCode MDx 3000 platform and distribute them into select Asian markets, Applied BioCode said.
The platform is based on a 96-well microplate format and automates PCR amplification, hybridization, and detection steps.
Financial and other terms of the deal were not disclosed.
Applied BioCode President Winston Ho noted in a statement that PerkinElmer's sales channels in China and other parts o fAsia will accelerate the commercialization of the BioCode MDx 3000 system.